CNS Drugs

, Volume 17, Issue 15, pp 1119–1122 | Cite as

Treatment of Recurrent Depression

An Alternate Viewpoint
Commentary

References

  1. 1.
    Fava GA, Ruini C, Sonino N. Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. CNS Drugs 2003; 17(15): 1109–1117PubMedCrossRefGoogle Scholar
  2. 2.
    Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653–61PubMedCrossRefGoogle Scholar
  3. 3.
    Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093–9PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months’ remission. Am J Psychiatry 1997; 154: 31–6PubMedGoogle Scholar
  5. 5.
    Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280(19): 1665–72PubMedCrossRefGoogle Scholar
  6. 6.
    Thase ME, Nierenberg AA, Keller MB, et al., and the Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62: 782–8PubMedCrossRefGoogle Scholar
  7. 7.
    Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51: 753–61PubMedCrossRefGoogle Scholar
  8. 8.
    Gelenberg AJ, Arnow B, Borian FE, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003; 54: 806–17PubMedCrossRefGoogle Scholar
  9. 9.
    Kirsch I. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevent Treat 2002; 5: 1–12Google Scholar
  10. 10.
    Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevent Treat 1998; 1: 1–15Google Scholar
  11. 11.
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311–7PubMedCrossRefGoogle Scholar
  12. 12.
    Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11: 137–45PubMedGoogle Scholar
  13. 13.
    Montgomery SA, Roberts A, Patel AG. Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharm 1994; 9Suppl. 1: 49–53CrossRefGoogle Scholar
  14. 14.
    Montgomery SA, Reimitz P-E, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacology 1998; 13: 63–73CrossRefGoogle Scholar
  15. 15.
    Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992; 49: 782–7PubMedCrossRefGoogle Scholar
  16. 16.
    Reynolds III CF, Perel JM, Frank E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 1999; 156: 1177–81PubMedGoogle Scholar
  17. 17.
    Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295–9PubMedGoogle Scholar
  18. 18.
    Paykel ES, Scott J, Teasdaleet JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56: 829–35PubMedCrossRefGoogle Scholar
  19. 19.
    Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998; 55: 816–20PubMedCrossRefGoogle Scholar
  20. 20.
    Persons JB, Thase ME, Crits-Christoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry 1996; 53: 283–90PubMedCrossRefGoogle Scholar
  21. 21.
    American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993; 150Suppl. 4: 1–26Google Scholar
  22. 22.
    Parloff MB. Psychotherapy research evidence and reimbursement decisions: Bambi meets Godzilla. Am J Psychiatry 1982; 139: 718–27PubMedGoogle Scholar
  23. 23.
    Luborsky L, Diguer L, Seligman DA, et al. The researcher’s own therapy allegiances: a ‘wild card’ in comparisons of treatment efficacy. Clin Psychol Sci Pract 1999; 6: 95–106CrossRefGoogle Scholar
  24. 24.
    Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 1995; 63: 966–80PubMedCrossRefGoogle Scholar
  25. 25.
    Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations